ARGX

argenx SE develops and commercializes immunology treatments targeting severe autoimmune diseases and cancer. Headquartered in Breda, the Netherlands, with additional facilities in the United States and Japan, the company focuses on antibody-based therapies derived from its proprietary SIMPLE Antibody Platform. The company's lead product, VYVGART (efgartigimod), is approved in multiple countries for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), representing its primary revenue generator. argenx markets VYVGART directly in the United States through its commercial infrastructure and partners with Zai Lab for Greater China distribution. The company's pipeline includes efgartigimod subcutaneous formulation and empasiprubart, both in late-stage clinical trials for various autoimmune indications including immune thrombocytopenia and pemphigus. argenx employs approximately 1,000 people globally and reported revenues exceeding $1 billion in 2023, primarily from VYVGART sales. The company maintains a partnership model for its SIMPLE Antibody Platform, having established collaborations with AbbVie, Zai Lab, and other pharmaceutical companies. Recent developments include the 2023 acquisition of Breda Pharma to strengthen its Dutch operations and expanded label approvals for VYVGART in additional indications. argenx operates as a fully integrated commercial-stage biotechnology company with manufacturing partnerships to supply its therapies globally.